Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas S Rector

Showing results (51-60 of 68) with videos related to

Pageof 7
Sort By:
European Journal of Heart Failure|October 11, 2014
A prediction model for sudden cardiac death in patients with heart failure and preserved ejection fractionSelcuk Adabag, Thomas S Rector, Inder S Anand, et al.
Journal of the American Heart Association|October 1, 2016
Cardiac Remote Ischemic Preconditioning Prior to Elective Vascular Surgery (CRIPES): A Prospective, Randomized, Sham-Controlled Phase II Clinical TrialSantiago Garcia, Thomas S Rector, Marina Zakharova, et al.
Molecular and Cellular Biochemistry|July 21, 2016
Examination of CK2α and NF-κB p65 expression in human benign prostatic hyperplasia and prostate cancer tissuesFatima Qaiser, Janeen H Trembley, Sarah Sadiq, et al.
Circulation|September 22, 2010
Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure TrialInder S Anand, Tibor Kempf, Thomas S Rector, et al.
Circulation. Heart Failure|January 24, 2012
Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the minnesota living with heart failure questionnaire in the irbesartan in heart failure with preserved systolic function (I-PRESERVE) trialThomas S Rector, Peter E Carson, Inder S Anand, et al.
Journal of Cardiac Failure|June 11, 2005
Clinical and analytical considerations in the study of health status in device trials for heart failureSharon-Lise T Normand, Thomas S Rector, James D Neaton, et al.
Circulation. Heart Failure|September 17, 2014
History of atrial fibrillation as a risk factor in patients with heart failure and preserved ejection fractionOludamilola W Oluleye, Thomas S Rector, Sithu Win, et al.
Journal of the American College of Cardiology|January 9, 2007
Influence of blood pressure on the effectiveness of a fixed-dose combination of isosorbide dinitrate and hydralazine in the African-American Heart Failure TrialInder S Anand, S William Tam, Thomas S Rector, et al.
Stroke|April 6, 2002
Occurrence of secondary ischemic events among persons with atherosclerotic vascular diseaseBarbara G Vickrey, Thomas S Rector, Steven L Wickstrom, et al.
Cerebrovascular Diseases (Basel, Switzerland)|May 26, 2004
Direct medical costs attributable to acute myocardial infarction and ischemic stroke in cohorts with atherosclerotic conditionsElizabeth M Sloss, Steven L Wickstrom, Daniel F McCaffrey, et al.
Pageof 7

Showing results (51-60 of 68) with videos related to

Sort By:
Pageof 7
European Journal of Heart Failure|October 11, 2014
A prediction model for sudden cardiac death in patients with heart failure and preserved ejection fractionSelcuk Adabag, Thomas S Rector, Inder S Anand, et al.
Journal of the American Heart Association|October 1, 2016
Cardiac Remote Ischemic Preconditioning Prior to Elective Vascular Surgery (CRIPES): A Prospective, Randomized, Sham-Controlled Phase II Clinical TrialSantiago Garcia, Thomas S Rector, Marina Zakharova, et al.
Molecular and Cellular Biochemistry|July 21, 2016
Examination of CK2α and NF-κB p65 expression in human benign prostatic hyperplasia and prostate cancer tissuesFatima Qaiser, Janeen H Trembley, Sarah Sadiq, et al.
Circulation|September 22, 2010
Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure TrialInder S Anand, Tibor Kempf, Thomas S Rector, et al.
Circulation. Heart Failure|January 24, 2012
Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the minnesota living with heart failure questionnaire in the irbesartan in heart failure with preserved systolic function (I-PRESERVE) trialThomas S Rector, Peter E Carson, Inder S Anand, et al.
Journal of Cardiac Failure|June 11, 2005
Clinical and analytical considerations in the study of health status in device trials for heart failureSharon-Lise T Normand, Thomas S Rector, James D Neaton, et al.
Circulation. Heart Failure|September 17, 2014
History of atrial fibrillation as a risk factor in patients with heart failure and preserved ejection fractionOludamilola W Oluleye, Thomas S Rector, Sithu Win, et al.
Journal of the American College of Cardiology|January 9, 2007
Influence of blood pressure on the effectiveness of a fixed-dose combination of isosorbide dinitrate and hydralazine in the African-American Heart Failure TrialInder S Anand, S William Tam, Thomas S Rector, et al.
Stroke|April 6, 2002
Occurrence of secondary ischemic events among persons with atherosclerotic vascular diseaseBarbara G Vickrey, Thomas S Rector, Steven L Wickstrom, et al.
Cerebrovascular Diseases (Basel, Switzerland)|May 26, 2004
Direct medical costs attributable to acute myocardial infarction and ischemic stroke in cohorts with atherosclerotic conditionsElizabeth M Sloss, Steven L Wickstrom, Daniel F McCaffrey, et al.
Pageof 7